1. Introduction {#s0005}
===============

Δ^9^-Tetrahydrocannabinol (Δ^9^-THC), which is a major component of Cannabis sativa, has psychoactive properties. It binds to endocannabinoid system receptors. Endogenous cannabinoids (endocannabinoids), their receptors and enzymes that degrade/synthesize these cannabinoids form the endocannabinoid system. Two types of cannabinoid receptors, CB(1) and CB(2), are defined up to date. Both of these receptor types are G protein-coupled receptors (GPRCs). CB(1) receptors are highly localized in the brain and cannabinoids show their psychoactive properties through these receptors ([@b0025]). Distribution of CB(2) receptors are more restricted and they are mostly found in immune cells and in some neurons ([@b0035]). Some studies showed that endocannabinoid system plays important role on proliferation and regulation of neurons of the central nervous system ([@b0005], [@b0065], [@b0070], [@b0075], [@b0080]). Rho/rho-kinase signalization pathway, which we evaluated in our study, is also important for cell proliferation and development ([@b0020], [@b0040], [@b0075]).

RhoA is a member of small GTPases and it transduce signals to intracellular downstream effectors ([@b0100]). RhoA's downstream effector is rho-kinase. Two rho-kinase isoforms are defined which are Rho-kinase β (ROCK1) and Rho kinase α (ROCK2) ([@b0050]). They play important roles on smooth muscle contraction, cell migration, apoptosis and cell proliferation ([@b0050]).

Since endocannabinoid system plays role on cell proliferation and development in neurons as well as rho/rho-kinase pathway, it is interesting whether chronic Δ^9^-THC treatment affects rho/rho-kinase signalization pathway or not.

2. Material and method {#s0010}
======================

Albino male mice (8 week old, balb/c) obtained from the Experimental Animal Center are used in study. This study was approved by the Animal Care Committee and Ethics Committee.

Mice are divided into three groups which are; control group, acute Δ^9^-THC treated group and chronic Δ^9^-THC treated group. All groups contained 8 mice. Δ^9^-THC (15 mg/kg) is applied by gavage once to acute Δ^9^-THC treated group after water is applied for 29 days by gavage. Δ^9^-THC (15 mg/kg) is applied by gavage three times a day to chronic Δ^9^-THC treated group for 30 days. Water is applied by gavage to control group under same experimental conditions for 30 days. At the end of the protocol described above, cervical dislocation is applied to the mice 1 h later after last gavage. Brain of the mice are stored in eppendorf tubes at −80 °C for later use in quantitative analysis.

Synthetic Δ^9^-THC Marinol (Unimed Pharmaceuticals Inc., Marietta, USA), that was dissolved at 0.1 mg/ml in 5.5% fat milk (w/v) in water, is used as the Δ^9^-THC source.

2.1. Quantitative analysis {#s0015}
--------------------------

### 2.1.1. Tissue homogenization {#s0020}

3 ml/gr Radio-immunoprecipitation Assay (RIPA) buffer, 30 μl phenylmethanesulfonyl fluoride (PMSF), 30 μl sodyum vanadate, 30 μl protease inhibitor is applied on frozen tissue samples that are stored in Eppendorf tubes then homogenates are obtained by using ultrosonication on those tubes on ice. Homogenates are then centrifuged at 10.000 RPM for 10 min and supernatants are taken and pellets are discarded.

### 2.1.2. Protein quantification {#s0025}

Bradford method is used to quantify the protein in homogenized tissues. By using Bovine serum albumin (1 μg/ml), 1, 2, 3, 5, 7, 8, 10 (μg/ml) standards are prepared. 10 μl is taken from every sample and completed to 100 μl by adding distilled water. 1 ml Bradford solution is added to standards and samples, vortexed and absorbances at 595 nm are measured manually. Protein quantification (μg/μl) is done according to the standard curve drawn in GraphPad Prism software (GraphPad Software, Inc., San Diego, USA).

### 2.1.3. Enzyme-Linked ImmunoSorbent Assay (ELISA) test {#s0030}

ELISA test is used to examine the expression and of RhoA (CUSABIO Inc., Maryland, USA), rho-kinase II (CUSABIO Inc., Maryland, USA) and the activity of rho-kinase (Cell Biolabs Inc., San Diego, USA).

2.2. Statistic analyzes {#s0035}
-----------------------

Results were expressed as means ± Standard Error of Mean (S.E.M.), and n refers to the number of animals used for each experiment. Differences in results between tissues were tested by one-way analysis of variance (one-way ANOVA) corrected for multiple comparisons (Bonferroni corrections). P values less than 0.05 were considered to be significant.

3. Results {#s0040}
==========

3.1. ELISA RhoA protein quantification {#s0045}
--------------------------------------

Chronic Δ^9^-THC treatment decreased expression of rhoA while acute Δ^9^-THC treatment had no meaningful effect ([Fig. 1](#f0005){ref-type="fig"}). Mean values of rhoA concentrations for control, chronic and acute Δ^9^-THC treated groups are found to be 2508 pg/ml (S.E.M. 240.3), 1858 pg/ml (S.E.M. 124.4), 2438 pg/ml (S.E.M. 191.4) respectively.Fig. 1Effect of chronic and acute Δ^9^-THC treatment on rhoA expression (n = 8). Statistical analysis: one-way ANOVA. Post hoc: Bonferroni. (\*: For control P \< 0.05).

3.2. ELISA Rho-kinase II enzyme quantification {#s0050}
----------------------------------------------

Chronic and acute Δ^9^-THC treatment did not change expression of rho-kinase II ([Fig. 2](#f0010){ref-type="fig"}). Mean values of rho-kinase II concentrations for control, chronic and acute Δ^9^-THC treated groups are found to be 44,809 pg/ml (S.E.M. 473.5), 44,958 pg/ml (S.E.M. 283.7), 45,081 pg/ml (S.E.M. 209.3) respectively.Fig. 2Effect of chronic and acute Δ^9^-THC treatment on rho-kinase II expression (n = 8). Statistical analysis: one-way ANOVA. Post hoc: Bonferroni.

3.3. ELISA Rho-kinase activity quantification {#s0055}
---------------------------------------------

Both Chronic and acute Δ^9^-THC treatment elevated activity of rho-kinase while acute Δ^9^-THC treatment increased the rho-kinase activity more than chronic Δ^9^-THC treatment ([Fig. 3](#f0015){ref-type="fig"}). Mean values of rho-kinase II concentrations for control, chronic and acute Δ^9^-THC treated groups are found to be 8.50 p-MYPT pg/mg (S.E.M. 0.46), 12.29 p-MYPT pg/mg (S.E.M. 1.19), 14.21 p-MYPT pg/mg (S.E.M. 1.05).Fig. 3Effect of chronic and acute Δ^9^-THC treatment on rho-kinase activity (n = 8). Statistical analysis: one-way ANOVA. Post hoc: Bonferroni. (\*: For control P \< 0.05. \# For 30 days P \< 0.05).

4. Discussion {#s0060}
=============

In this study, Rho/rho-kinase signalization pathway, which is important for intracellular signal transduction, is evaluated ([@b0020], [@b0040], [@b0075]). Authors showed that chronic Δ^9^-THC treatment decreased the expression of rhoA in the brain. This situation may be explained by chronic Δ^9^-THC treatment down-regulated rhoA expression by activating CB1 and CB2 continuously. Since CB1 and CB2 receptors are G protein coupled, change in rhoA level is expected. While chronic Δ^9^-THC treatment down-regulated rhoA expression, it did not change the level of rho-kinase which is downstream effector of rhoA. Both acute and chronic Δ^9^-THC treatment elevated the rho-kinase activity with respect to control group. However, chronic Δ^9^-THC treatment decreased the rho-kinase activity with respect to acute Δ^9^-THC treatment due to down regulation of the rhoA expression in the long term. A study showed that CB receptors also activate rac, ras and cdc42 proteins ([@b0055]). In the same study, it is also stated that active CB receptors caused the increase of phosphorylation of myosin light chains which are substrates of rho-kinase ([@b0055]). Also, same study emphasized the increase of rho-kinase activity as found in this study ([@b0055]).

Moreover, the reason for the increased activity of rho-kinase in the groups that are treated with acute and chronic Δ^9^-THC could be due to the stimulation of CB receptors with Δ^9^-THC. Since there is no Δ^9^-THC in the control group, CB receptors could be in an inactivated or low activity state.

Studies have shown that chronic Δ^9^-THC administration causes downregulation of CB1 receptors ([@b0045]). The reduction in RhoA may be due to the downregulation of Cb1 receptors, but further studies are needed to determine this. However, the downregulation of CB1 receptors and of RhoA may have had an additive effect on the reduction of the activity of the rho-kinase enzyme. Receptors such as dopamine (D) and serotonin (5ht) also function by activating RhoA ([@b0060], [@b0085]). In addition, chronic Δ^9^-THC administration changes the activation and expression of these receptors ([@b0030], [@b0095]).

CB receptors also causes elevation of intracellular calcium ([@b0010], [@b0090]). rhoA independent increase of rho-kinase activity may be caused by the elevation of intracellular calcium since it activates rho-kinase ([@b0010]). Furthermore, this study did not evaluate rhoA activity. Although its expression was decreased, its activity might be increased. To determine this, further studies are needed. Previous studies showed that rhoA acts to inhibit expression of cypin protein which has role on dendrite formation. Cypin is a newly identified protein in neurons. Chronic Δ^9^-THC treatment induced down-regulation of rhoA may cause elevation of cypin expression and may have benefit on cypin related diseases ([@b0025]). Furthermore, use of rho-kinase inhibitors and Δ^9^-THC together can be useful on rho-kinase related diseases. Since Δ^9^-THC treatment induces increase of rho-kinase activity, recent studies are also carried out to show the therapeutic benefits of Δ^9^-THC on some diseases like Alzheimer ([@b0015]).

This study showed that chronic Δ^9^-THC treatment down-regulated rhoA expression and did not change the expression level of rho-kinase which is downstream effector of rhoA. However, it elevated the rho-kinase activity.
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